{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:06:54Z","timestamp":1787497614845,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10072-025-08710-w","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:16:12Z","timestamp":1765952172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) following atezolizumab and bevacizumab treatment for hepatocellular carcinoma"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8159-3546","authenticated-orcid":false,"given":"Yi-Xiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Lei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"8710_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"Y Bagchi","year":"2021","unstructured":"Bagchi Y (2021) Engleman, immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223\u2013249. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741","journal-title":"Annu Rev Pathol"},{"key":"8710_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"Q Finn","year":"2020","unstructured":"Finn Q (2020) Ikeda, Galle, Ducreux, Kim, Kudo, Breder, Merle, Kaseb, Li, Verret, Xu, Hernandez, Liu, Huang, Mulla, Wang, Lim, Zhu, Cheng, Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"8710_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"D Wang","year":"2023","unstructured":"Wang D, Dougan (2023) Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer 9:543\u2013553. https:\/\/doi.org\/10.1016\/j.trecan.2023.04.002","journal-title":"Trends Cancer"},{"key":"8710_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","volume":"19","author":"P Haugh","year":"2020","unstructured":"Haugh P, Johnson (2020) Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf 19:479\u2013488. https:\/\/doi.org\/10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"key":"8710_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","volume":"24","author":"G Reynolds","year":"2019","unstructured":"Reynolds G (2019) Diagnosis and management of immune checkpoint Inhibitor-Associated neurologic toxicity: illustrative case and review of the literature. Oncologist 24:435\u2013443. https:\/\/doi.org\/10.1634\/theoncologist.2018-0359","journal-title":"Oncologist"},{"key":"8710_CR6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/wnl.0000000000011795","volume":"96","author":"B Marini","year":"2021","unstructured":"Marini B, Gigli V, Mu\u00f1iz-Castrillo (2021) Honnorat, Vogrig, neurologic adverse events of immune checkpoint inhibitors: A systematic review. Neurology 96:754\u2013766. https:\/\/doi.org\/10.1212\/wnl.0000000000011795","journal-title":"Neurology"},{"key":"8710_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s1474-4422(23)00369-1","volume":"23","author":"V-G Farina","year":"2024","unstructured":"Farina V-G, Mu\u00f1iz-Castrillo VZ (2024) Velasco, Guidon, Joubert, Honnorat, neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol 23:81\u201394. https:\/\/doi.org\/10.1016\/s1474-4422(23)00369-1","journal-title":"Lancet Neurol"},{"key":"8710_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1212\/wnl.0000000000200055","volume":"98","author":"W Liu","year":"2022","unstructured":"Liu W, Zhao MOG-IG-A (2022) Demyelination induced by pembrolizumab treatment in a patient with malignant melanoma. Neurology 98:501\u2013502. https:\/\/doi.org\/10.1212\/wnl.0000000000200055","journal-title":"Neurology"},{"key":"8710_CR9","doi-asserted-by":"publisher","first-page":"577259","DOI":"10.1016\/j.jneuroim.2020.577259","volume":"344","author":"N Kapadia","year":"2020","unstructured":"Kapadia N, Hannan, Farley, Pastula, Piquet (2020) Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab. J Neuroimmunol 344:577259. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577259","journal-title":"J Neuroimmunol"},{"key":"8710_CR10","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s10072-023-07252-3","volume":"45","author":"G Pedrero Prieto","year":"2024","unstructured":"Pedrero Prieto G, Romero G\u00f3mez, Miralles RP\u00e9rez, Estruch C (2024) Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma. Neurol Sci 45:2199\u20132202. https:\/\/doi.org\/10.1007\/s10072-023-07252-3","journal-title":"Neurol Sci"},{"key":"8710_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10637-021-01154-x","volume":"40","author":"L Wang","year":"2022","unstructured":"Wang L, Li, Li, Yang (2022) Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer. Invest New Drugs 40:151\u2013156. https:\/\/doi.org\/10.1007\/s10637-021-01154-x","journal-title":"Invest New Drugs"},{"key":"8710_CR12","doi-asserted-by":"publisher","unstructured":"DiMauro H (2025) Lee, Cohen, Flanagan, Riley, Goldman, Zamvil, Kunchok, Progressive Myelitis in a 63-Year-Old Woman: A Case Report From the National Multiple Sclerosis Society Case Conference Proceedings. Neurol Neuroimmunol Neuroinflamm. 12 e200382. https:\/\/doi.org\/10.1212\/nxi.0000000000200382","DOI":"10.1212\/nxi.0000000000200382"},{"key":"8710_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/s1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Marignier, Kim (2023) Brilot, Flanagan, Ramanathan, Waters, Tenembaum, Graves, Chitnis, Brandt, Hemingway, Neuteboom, Pandit, Reindl, Saiz, Sato, Rostasy, Paul, Pittock, Fujihara, Palace, diagnosis of Myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol 22:268\u2013282. https:\/\/doi.org\/10.1016\/s1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"8710_CR14","doi-asserted-by":"publisher","first-page":"642800","DOI":"10.3389\/fneur.2021.642800","volume":"12","author":"Valencia-Sanchez","year":"2021","unstructured":"Valencia-Sanchez (2021) Zekeridou, paraneoplastic neurological syndromes and beyond emerging with the introduction of immune checkpoint inhibitor cancer immunotherapy. Front Neurol 12:642800. https:\/\/doi.org\/10.3389\/fneur.2021.642800","journal-title":"Front Neurol"},{"key":"8710_CR15","doi-asserted-by":"publisher","unstructured":"Graus V, Mu\u00f1iz-Castrillo (2021) Antoine, Desestret, Dubey, Giometto, Irani, Joubert, Leypoldt, McKeon, Pr\u00fcss, Psimaras, Thomas, Titulaer, Vedeler, Verschuuren, Dalmau, Honnorat, updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 8. https:\/\/doi.org\/10.1212\/nxi.0000000000001014","DOI":"10.1212\/nxi.0000000000001014"},{"key":"8710_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11910-023-01250-w","volume":"23","author":"MG Gilligan","year":"2023","unstructured":"Gilligan MG, McKeon PND (2023) Curr Neurol Neurosci Rep 23:67\u201382. https:\/\/doi.org\/10.1007\/s11910-023-01250-w","journal-title":"Curr Neurol Neurosci Rep"},{"key":"8710_CR17","doi-asserted-by":"publisher","first-page":"1193211","DOI":"10.3389\/fneur.2023.1193211","volume":"14","author":"D Trentinaglia","year":"2023","unstructured":"Trentinaglia D, Carta, Chiodega, Ferrari (2023) Andreone, Maniscalco, Mariotto, investigating the association between neoplasms and MOG antibody-associated disease. Front Neurol 14:1193211. https:\/\/doi.org\/10.3389\/fneur.2023.1193211","journal-title":"Front Neurol"},{"key":"8710_CR18","doi-asserted-by":"publisher","unstructured":"de Aguiar, de Moraes (2019) Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors. Front Immunol 10:1023. https:\/\/doi.org\/10.3389\/fimmu.2019.01023","DOI":"10.3389\/fimmu.2019.01023"},{"key":"8710_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ijc.34332","volume":"152","author":"J Gu","year":"2023","unstructured":"Gu J, Lin Z, Cheng L, Zhang, Luo (2023) Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis. Int J Cancer 152:480\u2013495. https:\/\/doi.org\/10.1002\/ijc.34332","journal-title":"Int J Cancer"},{"key":"8710_CR20","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.21037\/tlcr-21-464","volume":"10","author":"T Bai","year":"2021","unstructured":"Bai T, Pacheco, Tachihara H, Zhang (2021) Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system. Transl Lung Cancer Res 10:2614\u20132624. https:\/\/doi.org\/10.21037\/tlcr-21-464","journal-title":"Transl Lung Cancer Res"},{"key":"8710_CR21","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"H Garcia","year":"2020","unstructured":"Garcia H, Sandler, Miles, Coleman, Deurloo, Chinot (2020) Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017","journal-title":"Cancer Treat Rev"},{"key":"8710_CR22","doi-asserted-by":"publisher","first-page":"103146","DOI":"10.1016\/j.msard.2021.103146","volume":"55","author":"S Rimkus","year":"2021","unstructured":"Rimkus S, Calich BGA-P, Callegaro L, Rovira S-G (2021) Leite, Drug-related demyelinating syndromes: Understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings. Mult Scler Relat Disord 55:103146. https:\/\/doi.org\/10.1016\/j.msard.2021.103146","journal-title":"Mult Scler Relat Disord"},{"key":"8710_CR23","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"N Schneider","year":"2021","unstructured":"Schneider N, Santomasso L (2021) Adkins, Anadkat, Atkins, Brassil, Caterino, Chau, Davies, Ernstoff, Fecher, Ghosh, Jaiyesimi, Mammen, Naing, Nastoupil, Phillips, Porter, Reichner, Seigel, Song, Spira, Suarez-Almazor, Swami, Thompson, Vikas, Wang, Weber, Funchain, Bollin, management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073\u20134126. https:\/\/doi.org\/10.1200\/jco.21.01440","journal-title":"J Clin Oncol"},{"key":"8710_CR24","doi-asserted-by":"publisher","unstructured":"Picca V, Birzu, Kramkimel, Hermine, Zahr (2021) Berzero, Psimaras, Anti-Interleukin-6 and Janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm 8. https:\/\/doi.org\/10.1212\/nxi.0000000000001073","DOI":"10.1212\/nxi.0000000000001073"},{"key":"8710_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","volume":"93","author":"F Campochiaro","year":"2021","unstructured":"Campochiaro F, Tomelleri, Ferrara L, De Luca (2021) Bulotta, Signorelli, Palmisano, Vignale, Peretto, Sala, Esposito, Garassino, Gregorc, Dagna, Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med 93:87\u201394. https:\/\/doi.org\/10.1016\/j.ejim.2021.07.016","journal-title":"Eur J Intern Med"},{"key":"8710_CR26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejca.2020.12.014","volume":"145","author":"P Basin","year":"2021","unstructured":"Basin P (2021) Michot, Lambotte, Cauquil, severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy. Eur J Cancer 145:230\u2013233. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.014","journal-title":"Eur J Cancer"},{"key":"8710_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12885-018-3997-2","volume":"18","author":"Y Narumi","year":"2018","unstructured":"Narumi Y (2018) Minami, Yamamoto, Takeguchi, Kano, Takahashi, Saito, Sawada, Terui, Katayama, Sasaki, Ohsaki, neuromyelitis Optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. BMC Cancer 18:95. https:\/\/doi.org\/10.1186\/s12885-018-3997-2","journal-title":"BMC Cancer"},{"key":"8710_CR28","doi-asserted-by":"publisher","first-page":"101447","DOI":"10.1016\/j.msard.2019.101447","volume":"37","author":"H Shimada","year":"2020","unstructured":"Shimada H, Tsunemi, Hattori, Nakagawa, Yokoyama, Hattori (2020) Neuromyelitis Optica spectrum disorder after treatment with pembrolizumab. Mult Scler Relat Disord 37:101447. https:\/\/doi.org\/10.1016\/j.msard.2019.101447","journal-title":"Mult Scler Relat Disord"},{"key":"8710_CR29","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1007\/s00415-021-10913-y","volume":"269","author":"Cantr\u00e9 Weiss","year":"2022","unstructured":"Weiss Cantr\u00e9, Zettl, Storch, Prudlo (2022) Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab. J Neurol 269:2778\u20132780. https:\/\/doi.org\/10.1007\/s00415-021-10913-y","journal-title":"J Neurol"},{"key":"8710_CR30","doi-asserted-by":"publisher","first-page":"806501","DOI":"10.3389\/fonc.2022.806501","volume":"12","author":"P Khimani","year":"2022","unstructured":"Khimani P, Whyte, Al-Zubidi C, Report (2022) Neuromyelitis Optica after treatment of uveal melanoma with nivolumab and ipilimumab. Front Oncol 12:806501. https:\/\/doi.org\/10.3389\/fonc.2022.806501","journal-title":"Front Oncol"},{"key":"8710_CR31","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12883-022-02987-6","volume":"22","author":"K Hirano","year":"2022","unstructured":"Hirano K, Nakayama, Takeda, Kishimoto, Takahashi, Kuwabara, Mori (2022) A case report of neuromyelitis Optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study. BMC Neurol 22:483. https:\/\/doi.org\/10.1186\/s12883-022-02987-6","journal-title":"BMC Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08710-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08710-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08710-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:04:44Z","timestamp":1773072284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08710-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["8710"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08710-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No identifiable information was disclosed in writing this case report; further ethical board approval was waived in accordance with local regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written consent was obtained from the patient\u2019s family for publishing his medical data for scientific purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"13"}}